Health for All in Africa – Our collaborations supporting the SDGs
Read more
COVID-19: An Unprecedented Mobilization of the Scientific Community On Thursday, 26 February 2020, Thomas Cueni spoke to Suisse media (RTS La Matinale). He explains how the innovative biopharmaceutical member companies of IFPMA are already helping and are taking practical steps to engage. Those companies with potentially relevant knowhow have teams of scientists checking their libraries...
Read moreAt WHO’s February Executive Board, The Global Self-Care Federation was among the UHC2030 Private Sector players to submit a statement. The statement calls for governments and other stakeholders to create an enabling environment for effective and structured private sector engagement, to accelerate progress on universal health coverage (UHC). Judy Stenmark, Director General of The Global Self-Care...
Read more
IFPMA and WHO Global Research and Innovation Forum IFPMA as the body representing the innovator biopharmaceutical industry in official relations with the UN, together with a number of its member companies were invited to the WHO Global Research and Innovation Forum on COVID-19 which took place on 11 and 12 February 2020 in Geneva. IFPMA...
Read moreThis article was originally published on Health Policy Watch on February 10, 2020. “We all have a vested interest to stop this epidemic,” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). As WHO on Tuesday convenes a Global Research & Innovation Forum to rapidly ramp up R&D, Cueni spoke with Health...
Read moreGeneva, February 10, 2020: Throughout the R&D-based biopharmaceutical industry, our first thoughts are with all those affected by the outbreak of the novel coronavirus (nCov-2019). The spread of the epidemic is a major public health threat for all affected countries; and we share the WHO’s concern for those countries with weaker health systems who could...
Read moreThis Statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, the Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association, and the Global Self-Care Federation (previously called the World Self-Medication Industry).
Read moreGeneva, 7 February, 2020: IFPMA welcomes the holistic approach of WHO to influenza preparedness, as well as the call for suggestions for further sensitizing Member States to the importance of timely influenza virus sharing, and for ways to promote influenza prevention and control strategies, including through the use of seasonal vaccination. We are concerned that...
Read moreGeneva, 7 February, 2020: IFPMA welcomes the addition of Neglected Tropical Diseases (NTDs) to the Executive Board agenda. The WHO’s development of the second roadmap on NTDs for 2021-2030 is timely, as we anticipate the coming to an end of the London Declaration – a coalition established in 2012, in which the biopharmaceutical industry pledged...
Read moreGeneva, 7 February, 2020: This statement is made by the International Federation of Pharmaceutical Manufacturers and Associations, supported by the International Council of Biotechnology Associations. IFPMA and ICBA would like to thank the WHO secretariat for its efforts to monitor progress on the overall implementation of the GSPA-PHI. The innovative biotechnology and biopharmaceutical industries engaged...
Read moreGeneva, 6 February, 2020: IFPMA strongly supports WHO’s plan to address the global burden of cervical cancer. The 90-70-90 goals are ambitious for every country and different approaches and timeframes will be required across settings. We urge WHO to take a strong leadership role in galvanizing the substantial investments in health systems and infrastructure needed...
Read more